Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMNLSFN)

Drug Name
Olezarsen Drug Info
Indication
Disease Entry ICD 11 Status REF
Familial chylomicronemia syndrome 5C80 Phase 3 [1]
Hypertriglyceridemia 5C80.1 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMNLSFN

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ApoC-III messenger RNA (APOC3 mRNA) TTXOZQ1 APOC3_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
ApoC-III messenger RNA (APOC3 mRNA) DTT APOC3 12.577 4.597 2.293 10.581
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Familial chylomicronemia syndrome
ICD Disease Classification 5C80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
ApoC-III messenger RNA (APOC3 mRNA) DTT APOC3 2.67E-01 0.1 0.59
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05130450) An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05681351) An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG). U.S.National Institutes of Health.
3 Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 Apr 6;43(14):1401-1412.